6-methoxy-1,2,3,4-tetrahydroquinolin-8-amine | 19279-83-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 6-methoxy-1,2,3,4-tetrahydroquinolin-8-amine
• 英文别名: 6-methoxy-1,2,3,4-tetrahydro-[8]quinolylamine；6-Methoxy-1,2,3,4-tetrahydro-[8]chinolylamin；6-methoxy-1,2,3,4-tetrahydro-quinoline-8-amine；8-amino-1,2,3,4-tetrahydro-6-methoxyquinoline；8-Amino-1,2,3,4-tetrahydro-6-methoxy-chinolin；6-Methoxy-1,2,3,4-tetrahydro-8-quinolinylamine
• CAS: 19279-83-5
• 化学式: C₁₀H₁₄N₂O
• 分子量: 178.234
• InChiKey: SMXAHIVKSAQNPL-UHFFFAOYSA-N

物化性质

• 沸点：
  175-185 °C(Press: 1 Torr)
• 密度：
  1.123±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  47.3
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  6-methoxy-1,2,3,4-tetrahydroquinolin-8-amine 在 戊醇 、 sodium 、 氯化铵 作用下， 生成 N⁴,N⁴-diethyl-N¹-(6-methoxy-1,2,3,4-tetrahydro-[8]quinolyl)-1-methyl-butanediyldiamine
  参考文献：
  名称：

  125.对合成抗疟药化学的贡献。第二部分 四氢吡喃醌

  摘要：

  DOI：

  10.1039/jr9460000610
• 作为产物：
  描述：

  8-氨基-6-甲氧基喹啉 在 乙醇 、 sodium 作用下， 生成 6-methoxy-1,2,3,4-tetrahydroquinolin-8-amine
  参考文献：
  名称：

  The Reaction of o-Phenylenediamine and of 8-Amino-1,2,3,4-tetrahydroquinoline Derivatives with Carbonyl Compounds

  摘要：

  DOI：

  10.1021/ja01181a015

文献信息

• Tricyclic benzimidazoles and their use as metabotropic glutamate receptor modulators
  申请人：Isaac Methvin

  公开号：US20070032469A1

  公开（公告）日：2007-02-08

  The invention provides for a compound of formula (I) or a pharmaceutically acceptable salt thereof: wherein R 1 , R 2 , R 3 , A, B, D, m, n, x, and y are defined as described in the specification. The invention additionally provides a pharmaceutically composition comprising the compound of formula I, together with a method of using the same to treat or prevent neurological and psychiatric disorders. The compounds are useful in therapy related to the treatment or prevention of mGluR2 receptor-mediated disorders.

  该发明提供了一个式(I)的化合物或其药用盐：其中R1、R2、R3、A、B、D、m、n、x和y的定义如规范中所述。该发明还提供了一种包含式I化合物的药用组合物，以及使用该组合物来治疗或预防神经学和精神疾病的方法。这些化合物在与mGluR2受体介导的疾病的治疗或预防相关的治疗中是有用的。
• [EN] SUBSTITUTED TRICYCLIC BENZIMIDAZOLES AS KINASE INHIBITORS<br/>[FR] BENZIMIDAZOLES TRICYCLIQUES SUBSTITUÉS UTILISÉS EN TANT QU'INHIBITEURS D'UNE KINASE
  申请人：SELVITA SA

  公开号：WO2014072435A1

  公开（公告）日：2014-05-15

  Disclosed are substituted tricyclic benzimidazoles compounds as defined herein in formula (I) or pharmaceutically acceptable salts thereof. The compounds of the invention selectively inhibit CDK8 and are therefore useful for treating diseases related to this kinase, especially colorectal and melanoma cancers and other solid and hemathological malignancies, autoimmune diseases and inflammatory diseases. Also disclosed are processes for preparing these compounds.

  本文揭示了定义如下的取代三环苯并咪唑化合物，其化学式为(I)，或其药学上可接受的盐。本发明的化合物选择性地抑制CDK8，因此对治疗与该激酶相关的疾病特别有用，包括结肠直肠癌、黑色素瘤和其他实体和血液恶性肿瘤、自身免疫疾病和炎症性疾病。还公开了制备这些化合物的方法。
• Imidazoquinolines containing other heterocyclic groups, useful as
  申请人：John Wyeth & Brother Limited

  公开号：US04703044A1

  公开（公告）日：1987-10-27

  The invention provides novel imidazoquinolines, processes for their preparation and pharmaceutical compositions containing them. The compounds have Formula I ##STR1## wherein A is a C.sub.1 -C.sub.4 straight or branched alkylene chain which may be saturated or unsaturated, B is a C.sub.2 -C.sub.4 straight or branched alkylene chain which may be saturated or unsaturated, R.sup.1 and R.sup.2 are the same or different and are hydrogen, C.sub.1-6 alkyl, C.sub.1-6 alkoxy, C.sub.1-6 alkoxyalkyl, C.sub.1-6 hydroxyalkyl, hydroxy, halogen, nitro, carboxy, carboxylic lower alkyl ester, carbamoyl, carbamoyloxy, cyano, loweralkanoyl, lower alkanoylamino or trifluoromethyl, Het is a heterocyclic group chosen from imidazolyl, imidazolinyl, benzimidazolyl, thiazolyl, thiazolinyl, quinolyl, piperidyl, pryidyl, benzothiazoly and pyrimidyl, any of which heterocyclic groups may be substituted, and x is 0 or 1, and pharmaceutically acceptable salts thereof. The compounds are anti-ulcer/anti-secretory agents.

  该发明提供了新型咪唑喹啉，其制备过程和含有它们的制药组合物。化合物具有公式I，其中A是C.sub.1-C.sub.4直链或支链烷基链，可以是饱和或不饱和的，B是C.sub.2-C.sub.4直链或支链烷基链，可以是饱和或不饱和的，R.sup.1和R.sup.2相同或不同，可以是氢，C.sub.1-6烷基，C.sub.1-6烷氧基，C.sub.1-6烷氧基烷基，C.sub.1-6羟基烷基，羟基，卤素，硝基，羧基，羧酸低烷基酯，氨基甲酰基，氨基甲酰氧基，氰基，低碳酰基，低碳酰胺基或三氟甲基，Het是从咪唑基，咪唑啉基，苯并咪唑基，噻唑基，噻唑啉基，喹啉基，哌啶基，吡啶基，苯并噻唑基和嘧啶基中选择的杂环基，其中任何一个杂环基可以被取代，x为0或1，以及其药学上可接受的盐。这些化合物是抗溃疡/抗分泌剂。
• Tricyclic Benzimidazoles and Their Use as Metabotropic Glutamate Receptor Modulators
  申请人：Isaac Methvin

  公开号：US20080318999A1

  公开（公告）日：2008-12-25

  The invention provides for a compound of formula (I) or a pharmaceutically acceptable salt thereof: wherein R 1 , R 2 , R 3 , A, B, D, m, n, x, and y are defined as described in the specification. The invention additionally provides a pharmaceutically composition comprising the compound of formula I, together with a method of using the same to treat or prevent neurological and psychiatric disorders. The compounds are useful in therapy related to the treatment or prevention of mGluR2 receptor-mediated disorders.

  该发明提供了式（I）的化合物或其药学上可接受的盐：其中，R1、R2、R3、A、B、D、m、n、x和y的定义如规范所述。此外，该发明还提供了包括式I的药学组合物，以及使用该组合物治疗或预防神经系统和精神疾病的方法。这些化合物在治疗或预防mGluR2受体介导的疾病的相关治疗中是有用的。
• SUBSTITUTED TRICYCLIC BENZIMIDAZOLES AS KINASE INHIBITORS
  申请人：SELVITA SA

  公开号：US20150274726A1

  公开（公告）日：2015-10-01

  Disclosed are substituted tricyclic benzimidazoles compounds as defined herein in formula (I) or pharmaceutically acceptable salts thereof. The compounds of the invention selectively inhibit CDK8 and are therefore useful for treating diseases related to this kinase, especially colorectal and melanoma cancers and other solid and hemathological malignancies, autoimmune diseases and inflammatory diseases. Also disclosed are processes for preparing these compounds.

  本发明涉及以下式（I）中所定义的取代三环苯并咪唑化合物或其药学上可接受的盐。该发明的化合物具有选择性地抑制CDK8，因此可用于治疗与该激酶相关的疾病，特别是结肠直肠癌和黑色素瘤等实体和血液恶性肿瘤、自身免疫疾病和炎症性疾病。本发明还涉及制备这些化合物的过程。